Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice

Hepatology

Volumn 47, Issue 1, 2008, Pages 225-235

  Shan, Weiwei ^a   Nicol, Christopher J ^c,e   Ito, Shinji ^c   Bility, Moses T ^a,b   Kennett, Mary J ^a   Ward, Jerrold M ^d   Gonzalez, Frank J ^c   Peters, Jeffrey M ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SOBRAN INC   (United States)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZOXYMETHANE; CARBON TETRACHLORIDE; CYTOCHROME; CYTOCHROME 2E1; ENVIRONMENTAL CHEMICAL; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT DISEASE; BILE DUCT HYPERPLASIA; CARCINOGENESIS; CATABOLISM; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION; LIVER TOXICITY; MALE; METABOLIC ACTIVATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE;

ANIMALS; AZOXYMETHANE; CARBON TETRACHLORIDE POISONING; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; HEPATITIS, TOXIC; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; PPAR DELTA; PPAR-BETA;

EID: 38649104434     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21925     Document Type: Article

References (67)

1. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-550.
2. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:244-251.
3. Shearer BG, Hoekstra WJ. Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem 2003;10:267-280.
4. Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 2000;21:823-826.
5. Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med 2005;83:774-785.
6. Lazar MA. PPAR gamma, 10 years later. Biochimie 2005;87:9-13.
7. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004;4:61-70.
8. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 2004;10:481-483.
9. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, et al. Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 2004;279:23719-23727.
10. Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPARb/d selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 2006;13:53-60.
11. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennen MJ, et al. Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res 2006;66:4394-4401.
12. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, et al. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-336.
13. Oliver WR, Jr., Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001;98:5306-5311.
14. Grimaldi PA. Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie 2005;87:5-8.
15. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006;103:3444-3449.
16. Manautou JE, Silva VM, Hennig GE, Whiteley HE. Repeated dosing with the peroxisome proliferator clofibrate decreases the toxicity of model hepatotoxic agents in male mice. Toxicology 1998;127:1-10.
17. Manautou JE, Tveit A, Hoivik DJ, Khairallah EA, Cohen SD. Protection by clofibrate against acetaminophen hepatotoxicity in male CD-1 mice is associated with an early increase in biliary concentration of acetaminophen-glutathione adducts. Toxicol Appl Pharmacol 1996;140:30-38.
18. Chen C, Hennig GE, Whiteley HE, Corton JC, Manautou JE. Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol Sci 2000;57:338-344.
19. Yuan GJ, Zhang ML, Gong ZJ. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol 2004;10:1047-1051.
20. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, De Jong J, et al. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003;124:184-201.
21. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, et al. Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol Cell Biol 2000;20:5119-5128.
22. Adamkiewicz J, Kaddatz K, Rieck M, Wilke B, Mullet-Brusselbach S, Muller R. Proteomic profile of mouse fibroblasts with a targeted disruption of the peroxisome proliferator activated receptor-beta/delta gene. Proteomics 2007;7:1208-1216.
23. Müller-Brüsselbach S, Kömhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J, et al. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ deficient mice. EMBO J 2007;26:3686-3698.
24. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 2005;280:9519-9527.
25. Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM. Inhibition of chemically-induced skin carcinogenicity by sulindac is independent of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). Carcinogenesis 2006;27:1105-1112.
26. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995;268:722-726.
27. Cheung C, Akiyama TE, Kudo G, Gonzalez FJ. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem Pharmacol 2003;66:2011-2020.
28. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001;276:39411-39418.
29. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996;271:12063-12067.
30. Yim SH, Ward JM, Dragan Y, Yamada A, Scacheri PC, Kimura S, et al. Microarray analysis using amplified mRNA from laser capture microdissection of microscopic hepatocellular precancerous lesions and frozen hepatocellular carcinomas reveals unique and consistent gene expression profiles. Toxicol Pathol 2003;31:295-303.
31. Sohn OS, Fiala ES, Requeijo SP, Weisburger JH, Gonzalez FJ. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Res 2001;61:8435-8440.
32. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-179.
33. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.
34. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-366.
35. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, et al. Critical roles of PPARbeta/delta in keratinocyte response to inflammation. Genes Dev 2001;15:3263-3277.
36. Taniguchi M, Takeuchi T, Nakatsuka R, Watanabe T, Sato K. Molecular process in acute liver injury and regeneration induced by carbon tetrachloride. Life Sci 2004;75:1539-1549.
37. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003;33:105-136.
38. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048-32054.
39. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759-763.
40. Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 2002;277:34176-34181.
41. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, et al. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005;65:832-841.
42. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-171.
43. Luckey SW, Petersen DR. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp Mol Pathol 2001;71:226-240.
44. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002;291:55-61.
45. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000;156:1253-1261.
46. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005;115:2330-2340.
47. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;280:3483-3492.
48. Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A 2002;99:2613-2618.
49. Honkakoski P, Negishi M. Regulatory DNA elements of phenobarbital- responsive cytochrome P450 CYP2B genes. J Biochem Mol Toxicol 1998;12:3-9.
50. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999;274:6043-6046.
51. Wong FW, Chan WY, Lee SS. Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol 1998;153:109-118.
52. Ali FY, Egan K, Fitzgerald GA, Desvergne B, Wahli W, Bishop-Bailey D, et al. Role of prostacyclin receptor versus PPAR{beta} with treprostinil sodium on lung fibroblast proliferation. Am J Respir Cell Mol Biol 2005;34:242-246.
53. Aung CS, Faddy HM, Lister EJ, Monteith GR, Roberts-Thomson SJ. Isoform specific changes in PPARalpha and beta in colon and breast cancer with differentiation. Biochem Biophys Res Commun 2006;340:656-660.
54. Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ, et al. Ligand activation of peroxisome proliferator-activated receptor-beta/ delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal 2007;19:1163-1171.
55. Fukumoto K, Yano Y, Virgona N, Hagiwara H, Sato H, Senba H, et al. Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett 2005;579:3829-3836.
56. Martinasso G, Maggiora M, Trombetta A, Canuto RA, Muzio G. Effects of di(2-ethylhexyl) phthalate, a widely used peroxisome proliferator and plasticizer, on cell growth in the human keratinocyte cell line NCTC 2544. J Toxicol Environ Health A 2006;69:353-365.
57. Matthiessen MW, Pedersen G, Albrektsen T, Adamsen S, Fleckner J, Brynskov J. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 2005;40:198-205.
58. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, et al. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol 2006;26:3266-3281.
59. Ou YC, Yang CR, Cheng CL, Raung SL, Hung YY, Chen CJ. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol 2007;563:49-60.
60. Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S, et al. Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 2004;122:971-983.
61. Varnat F, Heggeler BB, Grisel P, Boucard N, Corthesy-Theulaz I, Wahli W, et al. PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 2006;131:538-553.
62. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD, et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 2001;116:702-712.
63. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, et al. PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 2004;23:8992-8996.
64. Knight B, Yeap BB, Yeoh GC, Olynyk JK. Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis 2005;26:1782-1792.
65. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006;536:182-191.
66. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003;302:453-457.
67. Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, et al. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig Dis Sci 2007; In press. doi: 10.1007/s10620-006-9644-9.